Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis. (DEW)

23 settembre 2026 aggiornato da: Terry L. Wahls, University of Iowa

Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis: A Randomized Waitlist Controlled Trial (DEW Study)

The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing significant fatigue disability.

The main questions it aims to answer are:

  • Does the online wellness program lower fatigue after 3 months and further lower fatigue after 6 months?
  • Does the online wellness program improve anxiety, depression, and quality of life after 3 months and lead to additional improvements after 6 months? Researchers will compare participants who receive immediate access to the online wellness program with participants who continue their usual care and receive access to the program after the study ends.

Participants will:

  • Complete online surveys at the start of the study, at 3 months, and at 6 months. Each survey session takes less than 1 hour.
  • Complete a 7-day run-in period before randomization to confirm their interest and ability to complete study activities.
  • Be assigned by chance to either the online wellness program group or the wait-list control group.

Participants in the online wellness program group will:

  • Receive access to the "Creating Health" online course through the University of Iowa Canvas platform.
  • Work through five self-paced education modules over 6 months. Topics include nutrition, stress management, and physical activity.
  • Have access to monthly group coaching calls by Zoom.
  • Have access to an online exercise platform.
  • Have access to email and text support from the study team.

Participants in the wait-list control group will:

  • Continue their usual diet, lifestyle, and medical care during the 6-month study period.
  • Complete the same study surveys as the intervention group.
  • Receive full access to the online wellness program, online exercise platform and support materials after completing their final 6-month surveys.

At the end of the study, all participants will complete final surveys about their symptoms, quality of life, and their experience with the program. Active study participation ends after the 6-month assessments are completed.

Panoramica dello studio

Descrizione dettagliata

Detailed Description Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects nearly one million individuals in the United States. Progressive forms of the disease, including Primary Progressive Multiple Sclerosis (PPMS) and Secondary Progressive Multiple Sclerosis (SPMS), account for approximately 400,000 cases and are associated with substantial disability, fatigue, reduced quality of life, impaired mobility, mood disturbances, and cognitive challenges. Existing disease-modifying therapies have demonstrated effectiveness in reducing inflammatory disease activity but have limited impact on common disabling symptoms such as fatigue, anxiety, depression, and reduced health-related quality of life. Observational studies and preliminary intervention trials suggest that lifestyle factors, particularly diet quality, physical activity, and stress management practices, may improve symptoms and quality of life in people living with MS. However, high-quality randomized controlled trials evaluating integrated multimodal wellness interventions in individuals with progressive MS remain limited. This gap is particularly important because individuals with PPMS and SPMS often face barriers to in-person rehabilitation and wellness programs due to mobility limitations, transportation challenges, bowel and bladder dysfunction, and residence in rural communities. The purpose of the Evaluation of an Online, On demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis: A Randomized Waitlist controlled Trial (DEW Study) is to evaluate the effectiveness of a fully online, on-demand multimodal wellness intervention designed to reduce fatigue and improve quality of life among adults with progressive multiple sclerosis with significant fatigue disability. The intervention combines dietary education, structured exercise programming, stress management training, and behavioral support delivered through accessible virtual platforms. The DEW intervention consists of three primary components:1. Creating Health Online Wellness Course Delivered through the University of Iowa Canvas platform. Provides education regarding a modified Paleolithic dietary approach, with a Mediterranean dietary pathway available as an alternative. Emphasizes increased intake of nutrient-dense foods, including vegetables, and reduction of ultra-processed foods Includes practical resources related to meal planning, cooking skills, behavior change, and self-management strategies. 2. MS Gym Online Exercise Program A commercially available exercise platform specifically designed for individuals with multiple sclerosis. Provides mobility-level specific aerobic, resistance, balance, and functional movement exercises. Includes adaptations for seated and standing participation to accommodate varying levels of disability. 3. Stress Management Training. Participants are instructed in the 4-7-8 breathing technique, a structured breathing exercise intended to reduce stress and anxiety while supporting relaxation and sleep quality. Participants randomized to the intervention arm will also have access to monthly virtual group support sessions conducted via Zoom and facilitated by study personnel. These sessions utilize behavioral support and motivational interviewing principles to enhance adherence and self-efficacy. Participants may additionally communicate with the research team by email or text messaging for support throughout the intervention period. This study employs a randomized, waitlist-controlled design. Following informed consent, participants complete a 7-day run-in period designed to assess their ability to complete study procedures and baseline questionnaires. Participants who successfully complete baseline assessments will be randomized in a 1:1 ratio to either the intervention arm or a waitlist-control arm. Randomization is stratified by baseline fatigue severity. Participants assigned to the waitlist-control group will continue their usual diet, medical care, and lifestyle practices throughout the initial study period. They will receive general wellness information and monthly educational communications but will not have access to the wellness intervention during the primary comparison period. Following completion of the study assessments, waitlist participants will receive access to the Creating Health wellness course, the MS Gym exercise program, and a coaching session. Assessments are conducted electronically at baseline, Month 3, and Month 6 using validated patient-reported outcome measures. The primary outcome is change in fatigue severity, assessed using the Fatigue Severity Scale (FSS) at Month 3. Secondary outcomes include fatigue impact, health-related quality of life, mood, physical activity, dietary adherence, self-efficacy, social support, and participant acceptability of the intervention. Measures include the Modified Fatigue Impact Scale (MFIS), Multiple Sclerosis Quality of Life-54 (MSQOL-54), Hospital Anxiety and Depression Scale (HADS), Godin Leisure Time Exercise Questionnaire (GLTEQ), Physical Activity Vital Signs (PAVS), Mediterranean Diet Adherence Screener (MEDAS-14), Paleolithic Diet Adherence Screener (PDAS-12), Multiple Sclerosis Self-Efficacy Scale (MSSE), Multidimensional Scale of Perceived Social Support (MSPSS), Theoretical Framework of Acceptability questionnaire, and a Process Evaluation Questionnaire. The primary hypothesis is that participants receiving the DEW intervention will demonstrate greater improvements in fatigue at 3 months compared with participants receiving usual care. Secondary hypotheses are that intervention participants will experience improvements in quality of life, mood, physical activity, dietary adherence, self-efficacy, and perceived social support. Process evaluation measures will be used to identify barriers and facilitators to implementation and inform future dissemination of the intervention. By evaluating a scalable, fully virtual wellness program targeting fatigue and quality of life in progressive MS, this trial seeks to establish an accessible, non-pharmacologic approach that may help address important unmet needs among individuals living with progressive forms of multiple sclerosis.

Tipo di studio

Interventistico

Iscrizione (Stimato)

118

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242.
        • UI Health Care

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 45 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Definitive diagnosis of Primary Progressive MS (PPMS) or Secondary Progressive MS (SPMS) based on the 2024 revised McDonald Criteria and confirmed by the treating neurologist who also approves participation.

  2. Age 45 to 70 at the time of consent.

  3. Must be fluent in both speaking and reading English.

    *Study participant must be able to read and comprehend informed consent document and speak with study staff about study document content. Study staff will use discretion in determining whether the study participant can clearly communicate with staff and comprehend the study material during the consent call or prior to the call.

  4. Fatigue Severity Scale (FSS) score of greater than or equal to 4.

  5. Ability to prepare, or availability of someone in the household to prepare, home-cooked meals.

  6. Willingness to commit to the study diet, 4-7-8 breathing technique, and a structured exercise program.

  7. Access to high-speed internet with ownership of a device that can access the online programming and is capable of audio/video streaming.

  8. Completion of online surveys at Month 0 (baseline), Month 3, & Month 6.

Exclusion Criteria:

  1. Confirmation of taking insulin or coumadin.
  2. Documentation of relapse during the prior 4 weeks.
  3. Use of corticosteroids during the prior 4 weeks.
  4. Change or initiation of Disease Modifying Treatment (DMT) during the prior 4 weeks.
  5. Treatment for cancer by radiation or chemotherapy within the prior 12 months.
  6. Diagnosis of clinically significant heart, liver, or kidney disease, or history of oxalate kidney stones.
  7. Clinical diagnosis of psychiatric disease making study adherence difficult (e.g., schizophrenia) or an active eating disorder (anorexia, bulimia, binge eating, orthorexia).
  8. Measurement of Body Mass Index (BMI) < 19.
  9. Initiation of or change in medication to treat mood disorders in the prior 12 weeks.
  10. Documentation of moderate or severe mental impairment (greater than or equal to 5 errors) as measured by the validated Short Portable Mental Health Questionnaire (SPMHQ).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intervention arm

Wellness online program and virtual exercise platform

An online wellness course that teaches participants about behavior change, nutrition, exercise, stress management, and other wellness behaviors. Also includes access to an online exercise platform.

Comparatore placebo: Waitlist control

Continues with usual care as directed by their neurologist

Participant will continue with their usual diet and wellness behaviors.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fatigue Severity Scale (FSS) Score
Lasso di tempo: Baseline to 3 months

The Fatigue Severity Scale (FSS) is a 9-item patient-reported questionnaire that measures the impact and severity of fatigue on daily functioning. Participants rate each item on a scale from 1 (strongly disagree) to 7 (strongly agree). The total score is calculated as the mean of the 9 items. Higher scores indicate greater fatigue severity. An FSS score ≥4 is commonly used to identify clinically significant fatigue in multiple sclerosis

Baseline to 3 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fatigue Severity Scale (FSS) Score
Lasso di tempo: Baseline to 6 months

The Fatigue Severity Scale (FSS) is a 9-item patient-reported questionnaire that measures the impact and severity of fatigue on daily functioning. Participants rate each item on a scale from 1 (strongly disagree) to 7 (strongly agree). The total score is calculated as the mean of the 9 items. Higher scores indicate greater fatigue severity. An FSS score ≥4 is commonly used to identify clinically significant fatigue in multiple sclerosis

Baseline to 6 months
Change in Modified Fatigue Impact Scale (MFIS) Score
Lasso di tempo: Baseline to month 3 and month 6.

The MFIS evaluates the impact of fatigue on physical, cognitive, and psychosocial functioning during the previous 4 weeks.

Score Range: 0 to 84

Interpretation:

Lower scores indicate less impact of fatigue. Higher scores indicate greater fatigue-related impairment. A decrease in score represents improvemen

Baseline to month 3 and month 6.
Change in Multiple Sclerosis Quality of Life-54 (MSQOL-54) Physical Health Composite Score
Lasso di tempo: Baseline to month 3 and month 6

The MSQOL-54 is a disease-specific quality-of-life measure that combines the SF-36 with MS-specific domains. The Physical Health Composite measures the impact of MS on physical functioning and health.

Score Range: 0 to 100

Interpretation:

Higher scores indicate better physical health-related quality of life. An increase in score represents improvement.

Baseline to month 3 and month 6
Change in MSQOL-54 Mental Health Composite Score
Lasso di tempo: Baseline to month 3 and month 6

The Mental Health Composite of the MSQOL-54 assesses emotional well-being, cognitive health, social functioning, and mental health status.

Score Range: 0 to 100

Interpretation:

Higher scores indicate better mental health-related quality of life. An increase in score represents improvement

Baseline to month 3 and month 6
Change in Hospital Anxiety and Depression Scale Anxiety Subscale (HADS-A)
Lasso di tempo: Baseline to month 3 and month 6

The HADS-A is a 7-item patient-reported measure assessing symptoms of anxiety. Score Range: 0 to 21

Interpretation:

Lower scores indicate fewer anxiety symptoms. Higher scores indicate greater anxiety. A decrease in score represents improvement.

Severity Categories:

0-7: Normal 8-10: Borderline abnormal 11-21: Clinically significant anxiety

Baseline to month 3 and month 6
Change in Hospital Anxiety and Depression Scale Depression Subscale (HADS-D) Score
Lasso di tempo: Baseline to month 3 and month 6

The HADS-D is a 7-item patient-reported measure assessing symptoms of depression.

Score Range: 0 to 21

Interpretation:

Lower scores indicate fewer depressive symptoms. Higher scores indicate greater depression. A decrease in score represents improvement.

Severity Categories:

0-7: Normal 8-10: Borderline abnormal 11-21: Clinically significant depression

Baseline to month 3 and month 6
Change in Godin Leisure-Time Exercise Questionnaire (GLTEQ) Score
Lasso di tempo: Baseline to month 3 and month 6

The GLTEQ measures the frequency of mild, moderate, and strenuous leisure-time physical activity performed during a typical week.

Score Range: 0 to approximately 119+ (no fixed upper limit)

Interpretation:

Higher scores indicate greater participation in physical activity. An increase in score represents improvement

Baseline to month 3 and month 6
Change in Physical Activity Vital Sign (PAVS) Weekly Minutes of Moderate-to-Vigorous Physical Activity
Lasso di tempo: Baseline to month 3 and month 6

The PAVS estimates the number of minutes per week spent engaging in moderate-to-vigorous physical activity.

Score Range: 0 minutes to no fixed upper limit

Interpretation:

Higher values indicate greater physical activity participation. An increase in weekly minutes represents improvement

Baseline to month 3 and month 6
Change in Mediterranean Diet Adherence Screener (MEDAS-14) Score
Lasso di tempo: Baseline to month 3 and month 6

The MEDAS-14 assesses adherence to a Mediterranean dietary pattern using 14 dietary behavior questions.

Score Range: 0 to 14

Interpretation:

Higher scores indicate greater adherence to a Mediterranean diet. An increase in score represents improvement.

Baseline to month 3 and month 6
Change in Paleolithic Diet Adherence Screener (PDAS-12) Score
Lasso di tempo: Baseline to month 3 and month 6

The PDAS-12 assesses adherence to a Paleolithic dietary pattern based on 12 dietary criteria.

Score Range: 0 to 12

Interpretation:

Higher scores indicate greater adherence to a Paleolithic diet. An increase in score represents improvement

Baseline to month 3 and month 6
Change in Multiple Sclerosis Self-Efficacy Scale (MSSE) Score
Lasso di tempo: Baseline to month 3 and month 6

The MSSE assesses a participant's confidence in managing symptoms and daily challenges associated with multiple sclerosis.

Score Range: 14 to 84

Interpretation:

Higher scores indicate greater self-efficacy. An increase in score represents improvement

Baseline to month 3 and month 6
Change in Multidimensional Scale of Perceived Social Support (MSPSS) Score
Lasso di tempo: Baseline to month 3 and month 6

The MSPSS is a 12-item questionnaire that measures perceived social support from family, friends, and significant others.

Score Range: 12 to 84

Interpretation:

Higher scores indicate greater perceived social support. An increase in score represents improvement

Baseline to month 3 and month 6
Patient Determined Disease Steps (PDDS) Score
Lasso di tempo: Baseline to month 3 and month 6

The PDDS is a patient-reported measure of disability status in multiple sclerosis that correlates with the Expanded Disability Status Scale (EDSS).

Score Range: 0 to 8

Interpretation:

0 = Normal 8 = Bedridden Lower scores indicate less disability. A decrease in score represents improvement

Baseline to month 3 and month 6

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Theoretical Framework of Acceptability (TFA) Questionnaire
Lasso di tempo: At study conclusion (month 6)

The TFA Questionnaire evaluates participant perceptions of intervention acceptability, including burden, perceived effectiveness, ethicality, self-efficacy, and overall satisfaction.

Score Range: 1 to 5 per item (summary score calculated as mean response)

Interpretation:

Higher scores indicate greater acceptability of the intervention.

At study conclusion (month 6)
Process Evaluation Questionnaire (PEQ)
Lasso di tempo: At study conclusion (month 6)

The PEQ is a study-specific questionnaire used to identify facilitators and barriers to participation, as well as participant experiences with intervention delivery and adherence.

Score Range: Varies by item

Interpretation:

Descriptive measure used to assess implementation, feasibility, and participant feedback.

Higher scores on scaled items generally indicate more favorable perceptions of the intervention.

At study conclusion (month 6)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

15 novembre 2029

Completamento dello studio (Stimato)

15 dicembre 2030

Date di iscrizione allo studio

Primo inviato

15 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 settembre 2026

Primo Inserito (Effettivo)

21 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

After publication of results, relevant IPD published data will be shared for scientists who are conducting meta-analyses with a published protocol for PROSPERO registered meta-analysis.

Periodo di condivisione IPD

The IPD would be available one year after the primary outcomes data has been published.

Criteri di accesso alla condivisione IPD

Scientists with an academic appointment who wish to use IPD in a meta-analysis registered with Prospero and have published their protocol for the proposed meta-analyses are eligible to request access to the data. Proposals requesting access to the data should include the published protocol for the proposed meta-analysis and which specific data elements are being requested. The scientist should reach out to the study PI via their academic email with the requested documents. The scientists will provide their name, email, phone number and physical address at their institution. After reviewing the proposed meta-analysis and approval of the request by the PI, an outgoing material transfer agreement will be initiated by the PI via the University of Iowa Department of Sponsored Programs outlining terms of the data use. Upon completion of the data use agreement, the method of transfer of data elements will be mutually determined.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi